GlassScriptPhysician profile
Kayla E Putman
NPI 1932685237
$2,155.90
in general payments reported to CMS, 2019-2025
24 companies · $624 in 2025
The $624 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $219 · 2023: $531 · 2024: $782 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $390.94 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $364.19 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.11 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $179.64 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.64 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $118.08 | 2023-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $97.22 | 2024-2025 | |
| Shield Therapeutics INC | $95.48 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $92.96 | 2022-2024 | Rexulti |
| Ucb, INC. | $70.91 | 2023 | Briviact, Nayzilam |
| Lundbeck LLC | $51.22 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $49.33 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $37.25 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $34.00 | 2023 | Xarelto, Spravato |
| Astellas Pharma US INC | $30.23 | 2023 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $28.52 | 2024-2025 | Gemtesa |
| Dexcom, INC. | $24.57 | 2025 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $24.24 | 2023 | Belbuca |
| Sanofi-Aventis U.S. LLC | $21.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.69 | 2023 | |
| Avanir Pharmaceuticals, INC. | $17.17 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.78 | 2022 | |
| Organogenesis INC. | $16.36 | 2025 | Puraply Wound Matrix |
| E.R. Squibb & Sons, L.L.C. | $14.14 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Putman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.